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KEY POINTS
 Symmetric dimethylarginine (SDMA) is a new kidney biomarker that accurately reflects
glomerular filtration fate (GFR).
 SDMA level increases earlier in chronic kidney disease (CKD), on average with 40% reduc-
tion of GFR, compared with up to 75% reduction needed to increase creatinine level.
 Unlike creatinine, SDMA is not affected by lean body mass so it is a more sensitive indi-
cator of kidney function in patients with muscle loss.
 The validated immunoassay for SDMA, the IDEXX SDMA test, is a clinically relevant and
reliable tool for diagnosing early CKD in small animals when creatinine level is still within
the reference interval.
 SDMA was added to the International Renal Interest Society CKD guidelines to comple-
ment creatinine testing in staging early and advanced disease.INTRODUCTION
The diagnosis and management of chronic kidney disease (CKD) is a routine part of
clinical small animal practice. CKD is a common problem seen throughout the lives
of pets but increases in frequency as pets age. The prevalence of CKD has recently
been identified to be greater than previously reported.1 Patients diagnosed with
CKD are often managed successfully for years by the partnership of a diligent veter-
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dardized and informed management practices to address common complications.2
Symmetric dimethylarginine (SDMA), a novel kidney biomarker, permits earlier diag-
nosis of kidney disease than traditional creatinine testing, and has been included pro-
visionally as part of the IRIS CKD guidelines, as modified in 2015, for staging of both
early and advanced CKD.2 On diagnosis of CKD, veterinarians should investigate for
underlying conditions and complications that could be treated. Staging of CKD allows
customized patient management for the best possible outcome.DISCOVERY
SDMAwas first identified in 19703 and later characterized as a molecule that is primar-
ily cleared by the kidneys. SDMA emerged as a candidate kidney biomarker during in-
vestigations into the pathogenicity of a closely related compound, asymmetric
dimethylarginine (ADMA), in people with advanced CKD.4 Vallance and colleagues4
found increased concentrations of both dimethylarginines, SDMA and ADMA, in a
group of hemodialysis patients. They concluded that ADMA was a potent inhibitor
of nitric oxide (NO) synthesis and proposed that ADMA might be contributing to the
hypertension, immune dysfunction, and cardiovascular disease that complicate
CKD.4 They also recognized that significant metabolism of ADMA occurs before it rea-
ches the kidney, whereas SDMA was primarily cleared by the kidney, which further
differentiated the two molecules. SDMA’s value as a kidney biomarker was not iden-
tified. Because no active role for SDMA was identified in the pathogenesis of CKD and
their focus was more on hypertension and heart disease, SDMA was not the immedi-
ate target of additional research in methylated arginines.5
In 1997, Marescau and colleagues6 reported a strong correlation between serum
and urine concentrations of SDMA and kidney dysfunction by estimating glomerular
filtration rate (GFR) with creatinine clearance (R of 0.916; P<.0001) in 135 people
with CKD, and suggested serum SDMA as a good marker of kidney disease. Serum
SDMA level increased as kidney function declined, as shown by GFR decline, in an in-
verse relationship, with negative correlation (R value). This work was later included as
one of 18 studies in a powerful meta-analysis that showed highly significant correla-
tions between SDMA and kidney function tests in people.7
In the first clinical study of SDMA in veterinary patients with spontaneous kidney dis-
ease, Jepson and colleagues8 reported that SDMA correlated well with creatinine (r5
0.741; P<.001) in 69 cats with CKD and hypertension.BIOCHEMISTRY
Methylarginine Synthesis
SDMA is a stable molecule that originates from intracellular proteins that play an inte-
gral role in basic cellular metabolism. SDMA and related compounds are produced in
the nucleus of all cells. Their formation occurs by obligate posttranslational modifica-
tion and methylation of arginine residues of various proteins and subsequent proteol-
ysis.7 The molecular structures of arginine, SDMA, and other methylated products of
protein metabolism are shown in Fig. 1. The family of enzymes, arginine N-methyl-
transferases (PRMT), symmetrically methylate arginine residues of histones, spliceo-
somal Sm proteins, and receptor tyrosine kinases that generate SDMA and
NG-monomethyl-L-arginine (NMMA) on their hydrolysis.9,10 Other PRMT enzymes
asymmetrically methylate histones and myelin basic protein,11 which liberate ADMA
and NMMA when degraded.12,13 Note that although these substances are made
Fig. 1. Molecular structure for arginine and methylated arginines. NMMA, NG-monomethyl-
L-arginine.
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are very different.
Elimination
SDMA’s small molecular size (molecular weight [MW], 202 g/mol)14 and positive
charge allow it be freely filtered by glomerular filtration. Because SDMA is largely
excreted by the kidney, it is a good candidate biomarker for kidney function, whereas
highly protein-bound ADMA undergoes extensive metabolism by the tissue-specific
enzyme dimethylarginine dimethylaminohydrolase.7,13 In a 2011 review, Schwedhelm
and Bo¨ger5 estimated the renal excretion of SDMA to be greater than or equal to 90%,
with putative cleavage of the remainder by an unnamed enzyme. In contrast, only
about 20% of ADMA is excreted into the urine.5 The extensive renal clearance of
SDMA explains its correlation with other kidney clearance markers and its potential
suitability as an endogenous kidney biomarker.
CURRENT CHALLENGES WITH ASSESSING KIDNEY FUNCTION
Glomerular Filtration Rate
Direct measurement of GFR is the gold standard for quantitative assessment of kidney
filtration but is not routinely performed on dogs and cats because of the need to
administer a suitable filtration marker and obtain multiple timed blood samples and/
or urine samples, which are both difficult for the pet and time consuming.15 Although
people might think that a gold standard is an agreed-on process, there are a variety of
products, methods, and calculations to formulate GFR and there are perceived diffi-
culties with each protocol. Renal clearance methods that measure the appearance
of the marker substance in the urine were once preferred to plasma clearance
methods, with inulin commonly regarded as the ideal marker substance because it
Relford et al944is safe and inert, and is eliminated solely via glomerular filtration, without tubular reab-
sorption or secretion.16 However, the complicated nature of the inulin assay and the
requirement for accurate and complete urine recovery have made inulin renal clear-
ance testing unpopular outside the research setting.17 Alternate markers validated
for GFR measurement in dogs and cats include endogenous or exogenous creatinine,
cystatin C, iohexol, and radiolabeled molecules,15 including [125I] sodium iothalamate
and [131I] sodium iodohippurate.17
Plasma clearance of iohexol and exogenous creatinine offer practical and accurate
methods to estimate GFR in a clinical setting. Iohexol is a commonly available iodin-
ated contrast agent that may be given by single intravenous bolus injection. Plasma
samples are collected at predetermined, accurately recorded times, usually 2, 3,
and 4 hours after injection, before assay of the iodine components by mass spectros-
copy or other methods, which is available only at a select few locations, without the
need for urine.18 Plasma clearance results are calculated using pharmacodynamics al-
gorithms from marker decline on successive samples and are reported as the volume
of plasma that has been cleared of the marker substance over a given interval of time,
in milliliters per minute per kilogram of patient body weight,17 ideally compared with a
cohort of normal animals of the same species, breed, and size.
GFR continues to be a valuable measure of kidney function, although the compli-
cated nature of testing and associated expense reduces the clinical utility of clearance
methods. To help solve this problem in human patients, clearance methods are often
replaced by calculated (rather than measured) estimates of GFR using serum creati-
nine (sCr) level, body weight, and various correction factors based on the patient’s
gender, age, and race, alone or in conjunction with a timed urine collection for a urinary
creatinine clearance.7 The muscle mass and protein intake of the individual should
also be considered. However, there is no standard agreement on which formula
should be used and each formula can provide a different GFR estimate, again making
estimating GFR difficult. Similar algorithms for estimating GFR from sCr level in dogs
and cats are inaccurate because of greater individual gender and breed variation.19
These challenges of determining GFR continue to fuel the investigation into endoge-
nous biomarkers of kidney function.7Poor Sensitivity and Specificity of Serum Creatinine Testing
Measurement of sCr level has been the most widely used indirect estimate of GFR in
veterinary medicine because its small MW20 and neutral charge allow it to be freely
filtered by the glomeruli. SCr has an inverse but nonlinear relationship to GFR; that
is, sCr level increases exponentially as GFR declines. The steep curvilinear relation-
ship between sCr and GFR poses a significant limitation to the sensitivity of sCr level
for detecting early kidney disease because significant changes in GFR are reflected by
modest or minimally detectable changes in sCr, and early kidney disease might be
missed.21 The converse is also true: in advanced disease, small changes in GFR
make a large impact on sCr level, but this may have fewer clinical implications. SCr
level has been shown to not increase beyond laboratory reference intervals until up
to 75% of functional renal mass has been lost. The sensitivity of sCr level can be
improved by establishing a baseline for each individual pet while in good health and
then trending sCr over time using a consistent laboratory and analytical method.21–23
Increases and degree of magnitude in sCr level cannot determine reversibility of the
kidney disease or localization to renal, prerenal, or postrenal sources.24 By the time
sCr level has increased in CKD, the nephron loss is often irreversible and long-term
prognosis may be poor.
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Although regarded as a specific marker of kidney filtration, sCr level may be signifi-
cantly increased in heavily muscled dogs, or significantly decreased in dogs and
cats with muscle loss.20 Comprehensive descriptions of the breed variability of sCr
are lacking, but the greyhound is often cited as a breed with higher than expected
sCr levels in health.25 Evaluating kidney function in patients with increased muscle
mass requires careful consideration of the patient’s general health status; complete
urinalysis findings, including appropriateness of the urine specific gravity; and any his-
tory, physical findings, or imaging results that suggest kidney disease. Creatinine level
can significantly underestimate the degree of kidney disease present when dogs or
cats lose muscle mass because of aging or any chronic disease, especially protein
wasting diseases, cancer, or advanced kidney disease. In these scenarios, sCr level
overestimates the degree of remaining kidney function.26,27 These common clinical
conditions create the need for a more sensitive and specific kidney biomarker.
A commonly overlooked cause of increases in sCr level is diet. A study in humans
shows that sCr level can increase by 20% after eating cooked meat.28 Studies in
dogs show a similar effect following ingestion of meat. Six dogs were each fed soft
moist, raw, and boiled meat in a crossover feeding trial. Following ingestion, sCr con-
centrations increased in all dogs; and a persistent increase was noted for several
hours in the dogs fed boiled meat. The raw and soft moist diets were associated
with an initial increase that was followed by a decline in sCr level.29 These findings
support the recommendation that, when measuring sCr level, the patient should be
fasted for an accurate determination of kidney function.
Analytical Variability of Serum Creatinine Measurements
The fact that diagnostic reagents for measurement of sCr level are economical and
widely available for reference laboratory and point-of-care testing has helped sCr to
become the major predictor of kidney function. However, the commonly used Jaffe
method is not specific for creatinine and, according to some estimates, noncreatinine
compounds may contribute as much as 45% to 50% to reported sCr values.18,20 The
modification to the Jaffe method has addressed some of these challenges. What has
remained problematic is that different laboratory reagents and methods of measure-
ment continue to result in nonstandardized laboratory-dependent reference intervals
for sCr level. Analytical variability within and between the creatinine assay is also a lim-
itation. SDMA is a novel biomarker that can help to clarify the inaccuracies and non-
kidney variables associated with sCr as a diagnostic.
Criteria for a Better Kidney Biomarker
Concentrations of soluble serum and urinary compounds that change consistently
with early kidney damage have been the focus of study in people with naturally occur-
ring kidney disease and laboratory animal models of nephrotoxicity because the cur-
rent testing has limitations. As discussed previously, clinical testing for kidney disease
in most species relies on sCr measurement. In addition, although sCr seems to satisfy
the definition of a biomarker proposed by Puntmann,30 namely that “A biomarker is a
characteristic that can be objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes or pharmacological responses
to a therapeutic intervention,”30 it has limitations and the authors suggest criteria for
a better biomarker than sCr.
In the clinical setting, sCr is primarily a diagnostic and staging test. A better kidney
biomarker should be more sensitive and specific than sCr, compared with the gold
standard, with the clear ability to predict or exclude disease in an individual patient
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Receiver operating curves generating R values assist with this comparison. Bio-
markers for diagnosing acute conditions, like acute kidney injury, should appear early
and in proportion to the magnitude of the insult, with analysis available in real time,
especially at the point of care.30
For accurate monitoring of chronic conditions, such as CKD, a biomarker with nar-
row biological variability improves the assessment of longitudinal changes.30 A good
kidney biomarker should perform consistently in individual patients regardless of
whether they are aged, underweight, with variable nutrition, or affected with multiple
concurrent health concerns. The candidate biomarker for CKD should then be studied
to show that it has a positive impact on patient outcome, with improved quality of life
and survival times, compared with other methods.
Early studies of rodent and dog remnant kidney models of CKD support SDMA as an
endogenous kidney biomarker. SDMA correlated well with creatinine clearance after
partial nephrectomy in rats31 and with creatinine and blood urea nitrogen (BUN) levels
in rats after total nephrectomy.32 In 10 dogs undergoing partial or complete nephrec-
tomy, plasma SDMA concentrations increased with reductions in renal mass and
correlated well with GFR by inulin clearance (r value of 0.851; P<.0001) and with
sCr (r value of 0.749; P 5 .0013).33
Reviewing 18 early studies of 2136 human patients, Kielstein and colleagues7 found
that systemic SDMA concentrations correlated highly with GFR by inulin clearance
(R5 0.85; confidence interval, 0.76–0.91; P<.0001), as well as with sCr (R5 0.75; con-
fidence interval, 0.46–0.89; P<.0001), concluding that SDMA should be further inves-
tigated as a marker of renal function.7 In recent GFR studies using continuous infusion
of very-low-dose of iohexol, SDMA accurately and precisely estimated GFR in people,
and was more sensitive than sCr.34 In people with and without CKD, SDMA outper-
formed creatinine and creatinine-based equations in estimating kidney function
compared with measured GFR.35
These cumulative data from animal experiments and studies in people supported
the investigation of SDMA as a kidney biomarker for cats and dogs.SYMMETRIC DIMETHYLARGININE CORRELATES WITH GLOMERULAR FILTRATION RATE
Dogs with X-linked Hereditary Nephropathy
Nabity and colleagues22 recently published a prospective foundational study evalu-
ating SDMA as a marker for kidney disease in a colony of dogs with progressive
x-linked hereditary nephropathy (XLHN). They validated the SDMA assay for dogs us-
ing liquid chromatography–mass spectroscopy (LC-MS), then compared serial SDMA
measurements with sCr and GFR by exogenous plasma iohexol clearance in a cohort
of 8 affected male dogs and 4 unaffected littermate controls.
Intra-assay precision coefficient of variability (CV) of the LC-MS was 1.5% to 2.8%
(mean of 2.2%) and the inter-assay precision was 2.3% to 3.7% (mean of 2.7%),
both with 98% accuracy or greater, consistent with excellent analytical perfor-
mance.22 Preanalytical factors such as added hemoglobin, lipids, bilirubin, arginine,
monomethylarginine, ADMA, and homocitrulline did not interfere with SDMAmeasure-
ment. SDMA was highly stable in canine serum or plasma, resisting significant change
at room (20C) and refrigerator (4C) temperatures for 14 days.22
The subjects were studied over 37 weeks, with 6 of 8 affected dogs reaching the
targeted end point of sCr level greater than or equal to 5 mg/dL. In affected dogs,
SDMA level increased during progression from preclinical disease to end-stage
Fig. 2. Serum SDMA correlates with decreasing GFR by iohexol clearance in affected male
dogs with XLHN (R 5 0.95). (From Nabity NB, Lees GE, Boggess MM, et al. Symmetric dime-
thylarginine assay validation, stability, and evaluation as a marker for the detection of
chronic kidney disease in dogs. J Vet Intern Med 2015;29:1040; with permission.)
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a decrease in GFR (r 5 0.95), as shown in Fig. 2. An SDMA cutoff of greater than
or equal to 14 mg/dL identified, on average, a less than 20% decrease in GFR, which
was earlier than sCr by any comparison method, including using the sCr cutoff
for azotemia at greater than or equal to 1.2 mg/dL, serial trending of sCr levels,
or in comparison with sCr levels of unaffected littermates.22 Fig. 3 compares the
rapid clinical course of an affected dog with XLHN with an unaffected littermate
control.
Affected male dogs with XLHN have mutations in the genes coding for glomerular
type IV collagen and develop proteinuric end-stage kidney disease between 6 and
18 months of age, creating a convenient model of rapidly progressive CKD.36 The
heterozygous carrier females develop proteinuria as juveniles, but most have suffi-
cient normal glomerular basement membrane to maintain structural and functional
integrity, with clinical normalcy, adequate urine concentrating ability, and normal
sCr levels until they are about 5 years old.37 SDMA also correlated strongly with
the stable GFR of the colony’s female carriers (R2 5 0.85) (Mary Nabity, DVM,
PhD, DACVP, College Station, TX, personal communication, 2013.).
Cats, Azotemic and Nonazotemic
In a retrospective analysis, SDMA level was measured by LC-MS on previously frozen
serum samples from 10 client-owned cats and compared with their plasma creatinine
concentrations and GFRs by exogenous plasma iohexol clearance from the same
date. Serum SDMA levels and GFR were correlated strongly (R2 5 0.82; P<.001)
across a range of GFRs from 0.54 to 2.37 mL/min/kg (Fig. 4), whether cats were
azotemic or not.38
REFERENCE INTERVAL DEVELOPMENT
Reference intervals for dogs and cats were established following Clinical Laboratory
Standards Institute (CLSI) guidelines39 to facilitate the continued development of
SDMA as a clinical tool to measure kidney function.
Fig. 3. Typical clinical course of progressive kidney disease over 55 weeks in a dog with XLHN
compared with control litter mate, showing increasing SDMA and sCr levels as GFR declines.
(A) The dog Yale represents an age-matched control from the litter. His results show an
initial decline in GFR with maturation, seen in all the control pups, that plateaued after
30 weeks, with stable GFR, sCr level, and SDMA level. (B) In contrast, the affected dog Yachi’s
results show a progressive decline in kidney function beginning at approximately 15 weeks
that reached the study end point of sCr level greater than or equal to 5 mg/dL at approxi-
mately 38 weeks of age. SDMA concentration increased as sCr level increased and GFR
decreased. TAMU, Texas A&M University. (Courtesy of Mary Nabity, DVM, PhD, DACVP, Col-
lege Station, TX, personal communication, 2013.)
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Serum samples were collected from 122 clinically healthy, adult dogs (defined as
1 year of age) of varying gender, age, and breed attending a heartworm clinic. The
health status of each dog was based on physical examination; lack of any history
of constitutional signs or illness over the last 6 months; and prescription medication
limited to chemoprophylaxis for heartworm, fleas, and ticks. For each dog the
following information was recorded: diet, results of comprehensive complete blood
count with slide review, chemistry panel with electrolytes and total thyroxine concen-
trations, and when available results from a complete urinalysis, urine culture with
minimum inhibitory concentration and urine protein/creatinine ratio.
There were 151 dogs examined; 28 were excluded because of age (<1 year of age)
or health reasons. One dog was removed because of immeasurable sCr level. Dogs
ranged in age from 1 to 15 years, with a mean age of 4.7 years. Males and females
were equally represented. Body weights varied between 2.7 and 60 kg, with a wide
variety of body condition scores (data courtesy of IDEXX, Westbrook, ME.)
Fig. 4. The inverse relationship, with strong correlation (R2 5 0.82; P<.001), between serum
SDMA level (y axis) and GFR (x axis) in 10 client-owned cats with varied kidney function.
(Data from Braff J, Obare E, Yerramilli M, et al. Relationship between serum symmetric di-
methylarginine concentration and glomerular filtration rate in cats. J Vet Intern Med
2014;8:1699–701.)
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analyzed with a nonparametric model, using a 2-sided 95% confidence interval. After
exclusion of 2 outliers that were outside the mean, plus or minus 3 standard devia-
tions, the reference interval for healthy adult dogs was established at less than
14 mg/dL, as shown in Fig. 5.40Fig. 5. Canine serum SDMA concentration (LC-MS) (mg/dL) plotted on the x axis against pro-
portion of the reference population of healthy adult dogs (n 5 122) on the y axis. The refer-
ence interval was established at less than 14 mg/dL with nonparametric analysis. The box and
whiskers plot reflects the interquartile range, with outliers represented by dots. (From
Rentko V, Nabity M, Yerramilli M, et al. Determination of serum symmetric dimethylarginine
reference limit in clinically healthy dogs [ACVIM abstract P-7]. J Vet Intern Med 2013;27:750;
with permission.)
Fig. 6. Feline serum SDMA results (LC-MS) (mg/dL) plotted on the x axis against proportion of
the reference population of healthy adult cats (n 5 86) on the y axis. The reference interval
was established at less than 14 mg/dL with nonparametric analysis. The box and whiskers plot
reflects the interquartile range. (Courtesy of IDEXX, Westbrook, ME.)
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The reference interval for serum SDMA in cats was established similarly at less than
14 mg/dL (Fig. 6). Data were collected from 86 clinically healthy, adult cats, aged 6
to 15 years, comprising domestic short hair (DSH), domestic longhair, Siamese, and
ragdoll breeds. The cats were of both genders and weighed between 3.0 and 9.0 kg
(data courtesy of IDEXX, Westbrook, ME).
SYMMETRIC DIMETHYLARGININE LEVEL INCREASES EARLIER THAN CREATININE
With normal SDMA concentrations established for healthy dogs and cats, researchers
extended testing of its utility as a diagnostic tool for kidney disease.
Cats
For 21 cats with CKD living at the Hill’s Pet Nutrition colony, SDMA level wasmeasured
in banked frozen serum samples and compared with available documented sCr and
GFR assessments at various time points throughout the cats’ lives before and after a
diagnosis of CKD. In this retrospective longitudinal study, SDMA level increased to
greater than the reference interval on average 17 months earlier than sCr, with a range
of 1.5 to 48 months. SDMA level was found to be increased in the cats with CKD when
there was on average a 40% reduction in their GFR from themedian GFR of the healthy
cats in the samecolony. In 2 cats SDMA levelwas increasedwhen therewasonly a 25%
reduction in GFR from the designated normal for the colony. Serial results from a repre-
sentative case are provided in Fig. 7, showing an increase in SDMA to greater than the
reference interval 8 months before sCr. During this same interval, sCr level remained
stable and did not trend upward as the kidney disease progressed.41
Dogs
A similar study performed in 19 dogs with CKD showed that SDMA increased to
greater than the reference interval before sCr, in 17 of 19 dogs, on average 9.8 months
earlier, with a range of 2.2 to 27 months. SDMA level was significantly correlated with
GFR (r50.80; P<.001).42 The longitudinal laboratory data from an 11-year-old, male,
castrated Beagle in the colony are presented in Fig. 8 to show that SDMA level
increased to greater than the reference interval 19 months before sCr in this dog
with CKD.42 Postmortem renal histopathology confirmed lymphocytic/plasmacytic
Fig. 7. Mystic, born 2001, a 12-year-old, neutered male DSH, was diagnosed with CKD in
March of 2011 when GFR was 40% reduced from the expected mean of the colony. SCr level
is on the left y axis and SDMA is on the right y axis. Time is on the x axis. The solid black line
represents the upper end of the reference interval for both creatinine at 2.1 mg/dL and the
upper end of the reference interval for SDMA at 14 mg/dL. In the bar graphs, creatinine is
represented by the blue bars and SDMA is represented by the red bars. When a bar crosses
over the black line, then the analyte result is increased. SDMA level increased 8 months
before sCr, which was stable until a period of acute decompensation. (From Hall JA, Yerra-
milli M, Obare E, et al. Comparison of serum concentrations of symmetric dimethylarginine
and creatinine as kidney function biomarkers in cats with chronic kidney disease. J Vet
Intern Med 2014;28:1680; with permission.)
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glomerulosclerosis; changes that are consistent with CKD.43
SPECIFICITY OF SYMMETRIC DIMETHYLARGININE
There is considerable evidence across species supporting SDMA as a specific endog-
enous renal biomarker that is not influenced by extrarenal factors. In people, SDMA
level did not change with acute inflammatory response,44 hepatic disease,45,46 cardio-
vascular disease,47,48 or diabetes,49 unless there was concurrent kidney disease.
SDMA concentrations did not change in preeclampsic women receiving oral arginine
supplementation.50
SDMA level was not significantly increased after vigorous exercise in sled dogs with
normal BUN values, and was not influenced by breed or gender in a cohort of dogs,
unlike ADMA and nitric oxide metabolites, which are known markers of endothelial
function.51 In a group of Cavalier King Charles spaniels, SDMA level was not affected
by age or asymptomatic mitral regurgitation.52 Internal studies at IDEXX showed no
correlation between SDMA and serum arginine levels measured in dogs and cats
(R2 5 0.002). There was no correlation between the cardiac biomarker N-terminal
pro–brain natriuretic peptide and SDMA in approximately 300 dogs over a wide range
of results (R2 5 0.0043). Liver enzyme concentration, as a proxy for liver disease, and
SDMA level were not correlated: alkaline phosphatase (R2 5 0.01), alanine transami-
nase (R2 5 0.02), or aspartate aminotransferase (R2 5 0.05) (data courtesy of IDEXX).
Fig. 8. Nicholas, an 11-year-old, neutered male Beagle, was diagnosed with CKD in February
2010 when his GFR was decreased by 67% of the expected mean of the healthy dogs in the
same colony. Creatinine is on the left y axis and SDMA is on the right y axis. Time is on the x
axis. The solid black line represents the upper end of the reference interval for both creat-
inine at 2.1 mg/dL and the upper end of the reference interval for SDMA at 14 mg/dL. In the
bar graphs, creatinine is represented by the blue bars and SDMA is represented by the red
bars. When a bar crosses over the black line, then the analyte result is increased. (From Hall
JA, Yerramilli M, Obare E, et al. Serum concentrations of symmetric dimethylarginine and
creatinine in dogs with naturally occurring chronic kidney disease. J Vet Intern Med
2016;30:799; with permission.)
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dent of influences of lean body mass, so it is a more sensitive marker for kidney dis-
ease than sCr in patients with a wide variety of reasons for muscle loss. A study in
older cats with age-related loss of muscle mass, as measured by dual energy x-ray
absorptiometry, confirmed that creatinine level underestimates the loss of kidney
function as GFR declines. In contrast, SDMA level showed no correlation with lean
body mass. GFR declined with age, and serum SDMA level increased in concordance,
better identifying the function loss. These results support the conclusion that SDMA is
a more sensitive indicator of loss of kidney function.26 A complementary study in
healthy dogs showed comparable findings of a dependent correlation between lean
body mass and creatinine level (r 5 0.54; P 5 .0003), whereas SDMA level was not
influenced by total lean body mass (r 5 0.12; P 5 .45).27INTERNATIONAL RENAL INTEREST SOCIETY CHRONIC KIDNEY DISEASE GUIDELINES
INCLUSION
IRIS was created in 1998 to help veterinary practitioners better understand, diagnose,
and treat renal disease in dogs and cats. The board members created standardized
staging guidelines to educate and encourage the best practices for managing kidney
disease after diagnosis.
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guidelines, acknowledging SDMA as a renal function test to complement sCr in eval-
uating patients with early kidney disease, because it may be a more sensitive
biomarker of renal function than fasted blood creatinine concentrations.2 Persistent in-
creases in SDMA greater than 14 mg/dL suggest reduced kidney function and the pos-
sibility of IRIS CKD stage 1 in patients with sCr level less than the IRIS cutoff of 1.4 mg/
dL for dogs and 1.6 mg/dL for cats. Thus SDMA can help to identify dogs and cats in
IRIS stage 1 and early IRIS stage 2 in which clinical signs are absent or mild and creat-
inine level has not increased to greater than the reference interval.
The early recognition of kidney disease provides the opportunity to investigate for
an underlying cause, manage associated diseases and the CKD, and plan for moni-
toring the patient accordingly. Investigating when kidney disease is in the early stages
increases the likelihood of finding treatable causes such as upper urinary tract infec-
tion; vector borne diseases such as Lyme disease, ehrlichiosis, or leishmaniasis;
obstructive urolithiasis; or chronic toxicities. Investigating for complications such as
proteinuria and hypertension that may accelerate kidney disease is an important
aspect of substaging CKD.2 Even if no underlying cause or complications are identi-
fied, earlier diagnosis and treatment may slow the rate of progression of CKD and in-
crease the pet’s life span.53
Monitoring SDMA in patients with CKD can help to better identify progression of dis-
ease as dogs and cats lose weight, especially if it is associated with a loss of muscle
condition.26,27 According to the IRIS guidelines, patients with low body condition
scores that are in stage 2 or stage 3 based on creatinine level and that also show
an increased SDMA level greater than or equal to 25 mg/dL or 45 mg/dL, respectively,
may be staged inappropriately low and the degree of renal dysfunction may be under-
estimated. Treatment of clinical signs or laboratory findings of a more advanced stage
of CKDmight be appropriate; that is, CKD stage 3 and stage 4.2 Increased practitioner
awareness and use of a muscle condition scoring (MCS) system as proposed by the
World Small Animal Veterinary Association Global Nutrition Committee54 assists with
proper evaluation of patients with CKD. The MCS system is helpful in targeting muscle
loss because it is possible for pets to be overweight and still have muscle loss.55
Enhanced evaluation and recognition of kidney disease with SDMA and IRIS staging
may help veterinarians to better manage CKD and assist with objective patient moni-
toring and communication of measurable goals. Pet owners can be engaged to partic-
ipate in this important team effort to optimize their pets’ renal care for improved quality
and length of life. IRIS recognizes that, compared with creatinine, SDMA may be a
more sensitive biomarker of excretory renal function, and that SDMA can be a useful
adjunct for the early diagnosis of CKD, as well as a guide for management of more
advanced CKD. SDMA testing should be run alongside sCr, BUN, and a complete uri-
nalysis to provide a comprehensive picture of kidney function.THE IDEXX SYMMETRIC DIMETHYLARGININE TEST
Validation
The LC-MS analysis for SDMA, although extremely accurate and considered the gold
standard, can be costly and time consuming, and thus inconvenient to add to the
routine laboratory minimum data base for sick and well pets. The IDEXX SDMA test
is a novel, high-throughput, competitive homogeneous immunoassay using a
glucose-6-phosphate dehydrogenase conjugate and anti-SDMAmonoclonal antibody
to quantify SDMA in serum and plasma.56 The technique is especially useful when
developing an immunoassay for a small biomarker molecule such as SDMA,56 which
Relford et al954is less immunogenic because of its small size.5 The assay was validated following US
Food and Drug Administration and CLSI standards for dogs and cats, using healthy
and CKD populations.57 Accuracy was confirmed by comparing the results with the
LC-MS standard over a dynamic range of 5 to 100 mg/dL. In the range of 10 to
20 mg/dL, within-run precision was less than or equal to 7% CV, and total precision
was less than or equal to 10% CV.56,57
The reference interval for the IDEXX SDMA test, established at less than or equal to
14 mg/dL, is based on transference analysis of SDMA data by LC-MS from healthy
dogs and cats (data courtesy of IDEXX40), considering mean bias, method precision,
and whole-number rounding of the original data.
Clinical Use
The SDMA test is available from IDEXX Reference Laboratories. The IDEXX SDMA test
is performed along with all routine chemistries on a multichannel analyzer (Beckman
Coulter, Inc, Brea, CA). SDMA results are provided at the same time as all other chem-
istry results without a delay in the reporting time. Serum is the preferred sample type;
lithium heparin or EDTA plasma is also acceptable. The IDEXX SDMA test is not
affected by mild to moderate hemolysis or any degree of lipemia or icterus. An inter-
pretive comment is provided with all SDMA results to assist with interpretation along
with creatinine results. For patient results with increased IDEXX SDMA and sCr within
the reference interval, early kidney disease is likely and further investigation is indi-
cated, as suggested in Box 1.
SDMA complements traditional tests for kidney disease. To diagnose kidney dis-
ease, the patient’s clinical presentation, physical examination findings, and results
of laboratory testing and imaging should be considered. The clinical presentation in-
cludes the signalment, consisting of age, breed, and gender; any relevant history,
such as medication use, possible exposure to toxins, diet, and travel; with possible
exposure to infectious diseases that may be risk factors for kidney disease, such as
Lyme disease or leptospirosis.
In early CKD, clinical signs are often absent. With progression of CKD these signs
are more common:
 Polyuria and polydipsia
 Decreased appetite
 Weight loss
 LethargyBox 1
Interpretive criteria for the IDEXX SDMA test when SDMA level is increased and creatinine
level is within the reference interval
SDMA level is increased and creatinine level is within the reference interval, which indicates
that early kidney disease is likely. Most animals with early kidney disease have an SDMA level
between 15 and 20 mg/dL. Because SDMA level increases as kidney function decreases, SDMA
levels greater than 20 mg/dL are typically seen in more advanced disease along with an
increased creatinine level. SDMA is a more sensitive indicator of kidney function in poorly
muscled animals. A complete urinalysis should be performed to evaluate for inappropriate spe-
cific gravity, proteinuria, and other evidence of kidney disease. SDMA results may be slightly
higher (w1 mg/dL) in puppies, kittens, and greyhounds and results should be interpreted in
light of other findings.
(Courtesy of IDEXX, Westbrook, ME.)
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 Bad breath
Early physical examination changes are often subtle or absent, but typically prog-
ress with advancing disease. Common physical examination findings in CKD include:
 Palpable kidney abnormalities
 Evidence of weight loss
 Dehydration
 Pallor
 Oral ulcers
 Hypertensive retinopathy
Because signs and physical examination findings are inconsistent or absent in early
disease, relevant laboratory or imaging findings are necessary to assess kidney health.
Urinalysis results vary in early kidney disease, with progressive loss of concentrating
ability expected as the condition progresses. Inadequate concentrating ability is
defined for cats as urine with specific gravity less than 1.035 and for dogs less than
1.030.58 Making an early diagnosis of CKD commonly requires finding 1 or more of
the following results:
 sCr level increasing within the reference interval
 Persistently increased SDMA level greater than 14 mg/dL
 Abnormal kidney imaging
 Persistent renal proteinuria, especially over weeks to months
With the exception of changes in kidney size, shape, or architecture that may be
detected by examination or kidney imaging on the first visit (eg, finding small, irregular
kidneys), these diagnostic criteria for CKD must persist over time in stable patients.
Patients changing rapidly, with increasing SDMA level and the development of
azotemia, should be suspected of acute kidney injury or an active primary disease
and be evaluated aggressively.
With more advanced CKD, levels of both sCr and SDMA are chronically increased,
and urine becomes progressively more dilute. In advanced cases of renal disease,
SDMA can provide insight into the severity of disease because sCr level may be influ-
enced by loss of muscle mass and under-represent the severity of the disease. Rarely
do these patients present a diagnostic challenge to identify that kidney disease is pre-
sent; instead the focus turns to managing a known problem.
PATIENT DATA AND IMPACT
SDMA data collected to date support that kidney disease is more prevalent than was
previously reported, and increases with increasing pet age. In the first 750,000 or more
IDEXX SDMA tests performed in the United States, dog samples outnumbered cat
samples approximately 2 to 1. These samples showed that 11% of feline samples
and 6% of canine samples had an increase in creatinine level to greater than the refer-
ence interval. However, there was an additional 15% of cats and 6% of dogs identified
to have increased SDMA levels, whereas the creatinine level remained within the refer-
ence interval. These findings suggest that, by using SDMA, which is a more sensitive
biomarker, veterinarians have the potential opportunity to diagnose kidney disease 2.4
times more often in cats and 2.0 times more often in dogs, compared with the tradi-
tional use of sCr (Fig. 9) (data courtesy of IDEXX).
IDEXX data gathered also highlight that the prevalence of CKD increases with
increasing age and might exceed historical estimates that 1 in 3 cats59 and 1 in 10
Fig. 9. Patient results for the IDEXX SDMA test and paired creatinine tests expressed as a per-
centage of feline and canine samples tested suggest that kidney disease may be more preva-
lent than estimates based on creatinine testing alone. (Courtesy of IDEXX, Westbrook, ME.)
Relford et al956dogs60 develop CKD in their lifetimes based on creatinine alone. More than 50% of
cats more than 15 years of age had increased SDMA and normal or increased Cr
levels. In comparison, among dogs 15 years of age or older, 40% had increased
SDMA levels and possible kidney disease (data courtesy of IDEXX). The IDEXX
SDMA test data support Marino and colleagues’1 recent report that the prevalence
of CKD in cats older than 15 years was 86.2% (primarily IRIS CKD stage 1 and 2).SUMMARY
SDMAmay affect how veterinarians diagnose andmanage kidney disease in dogs and
cats. SDMA, a product of intranuclear protein metabolism, is freely filtered by the kid-
neys, and serum levels of SDMA correlate inversely with measurements of GFR in peo-
ple, rats, mice, dogs, and cats. SDMA was investigated as a potential clinical renal
biomarker for almost a decade, and a reference interval for SDMA has been estab-
lished in healthy dogs and cats, as measured by LC-MS.
SDMA is a sensitive and specific renal biomarker. Longitudinal studies of SDMA in
dogs and cats with CKD showed that SDMA level increased months earlier than sCr,
when there was on average a 40% reduction in GFR, whereas sCr level increases late,
when there is up to 75% reduction of GFR. Unlike sCr, SDMA is independent of lean
body mass, so it is a more sensitive marker for kidney disease than sCr in patients with
muscle loss. As a result of vigorous analysis and clinical review, SDMA has been
included in the updated IRIS guidelines to complement sCr in the diagnostic evalua-
tion and monitoring of CKD.
Early experience with the use of the IDEXX SDMA test, which is a new immunoassay
for SDMA, in a large patient population suggests that kidney disease is more prevalent
than was previously predicted by increased sCr levels alone. Kidney disease and
SDMA increase more frequently as dogs and cats progress in age, supporting histor-
ical data. Earlier diagnosis of kidney disease provides an opportunity for intervention
by investigation for underlying causes and complications associated with kidney dis-
ease. This, in turn, leads to more effective treatment and management.REFERENCES
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